Clinical Outcomes and Safety of Secukinumab in Thai Patients with Plaque Psoriasis: A 16-Week, Multicenter, Retrospective, Real-World Study
Background: Secukinumab, an interleukin 17A-inhibitor approved for the treatment of moderate-to-severe plaque psoriasis, has been well-studied in phase II and III trials and shown to have a sustained high-level of clinical efficacy with good safety profile and positive impact on patients' quali...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| 其他作者: | |
| 格式: | Article |
| 出版: |
2022
|
| 主題: | |
| 在線閱讀: | https://repository.li.mahidol.ac.th/handle/123456789/74821 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|